Role of diabetes in lung injury from acute exposure to electronic cigarette, heated tobacco product, and combustible cigarette aerosols

Michella Abi Zeid Daou  
American University of Beirut Medical Center

Alan Shihadeh  
American University of Beirut

Yasmine Hashem  
American University of Beirut Medical Center

Hala Bitar  
American University of Beirut

Alaa Kassir  
American University of Beirut

Nareg Karaoghlanian  
American University of Beirut

Assaad A. Eid  
American University of Beirut

Marwan El-Sabban  
American University of Beirut

Ghazi Zaatari  
American University of Beirut Medical Center

Ahmad Husari  
American University of Beirut Medical Center  
https://orcid.org/0000-0002-2317-1385

Research

**Keywords:** ECIG, HTP, CS, diabetes

**DOI:** https://doi.org/10.21203/rs.3.rs-81475/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background

Patients with diabetes are more vulnerable to the detrimental respiratory effects of combustible cigarette smoke (CS) when compared to the general population. Electronic cigarettes (ECIG) and heated tobacco products (HTP) are marketed as less harmful alternatives to CS. In this study, we compared the effects of acute ECIG, HTP and CS exposure on the lungs of type II diabetes versus non-diabetic mice in an animal model.

Methods

Type II Diabetic (Diab) and Non-Diabetic (Non-Diab) mice were divided into Control, ECIG, HTP and CS groups. Animals were exposed for 6 hrs./day to either air, ECIG, HTP or CS for seven days. Lung injury was determined by a) histopathology, b) wet to dry ratio, c) albumin concentration in bronchoalveolar lavage fluid, d) expression of TNF-α, IL-6, and IL-1β, e) reactive oxygen species production (ROS), and f) assessment of cellular apoptosis.

Results

Lung histology revealed increased edema and inflammatory cells in diabetic mice exposed to ECIG, HTP and CS. The expression of inflammatory mediators was, in general, more significant in the Diabetic groups as well. TNF-α expression, for example, was upregulated in Diab + HTP and Diab + ECIG but not in Non-Diab + HTP. ROS was significantly increased in Diab + CS, less in Non-Diab + CS and weakly noted in ECIG + Diab. Significant albumin leak was observed in HTP-exposed animals. CS exposure worsened lung injury in Diab when compared to Non-Diab mice.

Conclusion

Comorbid medical conditions like diabetes may amplify ill effects CS, ECIG or HTP exposure.

What Does This Study Add?

- Diabetes may pre-dispose ECIG and HTP users to added lung injury.
- HTP and ECIG aerosol exposure elicit lung injury even in the absence of diabetes.

Introduction

Combustible cigarette smoke (CS) contains toxicants that are harmful to human health and that result in organ damage and early death [1]. Chronic obstructive pulmonary disease (COPD), for example, is
associated with CS and exposure and was projected to become the third most common cause of death by 2020 [2, 3]. Electronic cigarettes (ECIG) and heated tobacco products (HTP) are marketed as less harmful or not harmful alternatives to combustible cigarettes, and sometimes as effective tools for smoking cessation [4]. ECIGs are battery-powered devices that heat and vaporize a liquid solution that usually contains nicotine, propylene glycol, glycerin, and other ingredients [5]. To attract more users, ECIG manufacturers are now adding a wide range of flavors to the liquid solutions [6]. Some ECIG users are advocating for ECIG exemption from indoor-smoking policies [7]. Despite the inconclusive data on their long-term health effects and population-wide impact on tobacco use patterns, ECIGs continue to penetrate the global markets with increased sales and consumption [8, 9].

Another category of tobacco products is known as heat-not-burn or heated tobacco products (HTP). These products involve electrically heating a tobacco filler similar to that found in combustible cigarettes. HTPs produced by Phillip Morris International are marketed under the IQOS brand, which has been cleared for marketing as a Modified Risk Tobacco Product by the US Food and Drug Administration [10]. IQOS uses a battery-powered heating blade to reportedly heat the filler to a temperature of 350°C, producing an aerosol that mimics that of a combustible cigarette, but with reduced toxicant content [11]. The adverse effects of HTP use are not thoroughly tested and scientifically established.

Type II diabetes is a major global health problem and it is recognized that cardiovascular and respiratory complications are augmented in cigarette smokers [12, 13]. Smoking is associated with significantly higher rates of mortality and morbidity in diabetic than in non-diabetic populations [14]. To the best of our knowledge, the effects of ECIG or HTP on subjects with comorbid medical conditions like diabetes have not been examined. In this study, we studied whether ECIG or HTP exposure exaggerates the respiratory effects in diabetics when compared to non-diabetics in an animal model. In addition, the study compared the effects of ECIG and HTP to the detrimental effects of CS exposure in diabetic and non-diabetic mice.

**Methods**

**Animals:**

All animal procedures were conducted according to the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at the American University of Beirut. Four-month-old non-obese type II female diabetic FVB-Tg (Ckm-1GF1R*K1003R)1Dlr/J mice weighing 22 to 25 grams (Diab) and age matching (Non-Diab) FVB-Tg adult female mice were kept in a temperature-controlled room and on a 12/12 hrs dark/light cycle and had standard chow and water access except when mice were placed in the exposure apparatus. Female mice were selected because of their established vulnerability to CS when compared to males. The ECIG, HTP, CS or exposure apparatus (ONARES, CH Technologies, USA) consists of a smoke generator, mixing/conditioning chamber and a twelve “nose only” rodent exposure carousel. One port was dedicated for sampling analysis, and the remaining 11 ports were used for animal exposure. Non-Diabetic mice
were each divided into four groups: Control Non-Diab, Non-Diab + ECIG, Non-Diab + HTP and Non-Diab + CS.

Similarly, diabetic mice were divided into: Control Diab, Diab + ECIG, Diab + HTP and Diab + CS. Before placement in the exposure carousel, animals were acclimated to retainers for one week. As described previously [15], mice were then positioned in retainers and placed into the compartments of the carousel and received a continuous flow of air or air mixed with ECIG or HTP or CS aerosols. Mice were exposed for seven consecutive days, twice daily (am session and pm session). Each session lasted for 3 hrs.

At the conclusion of the experiment, animals were anesthetized, and the trachea was cannulated with polyethylene tubing. Animals were exsanguinated by severing the aorta. The diaphragm was dissected to allow free lung expansion. The left lung was clipped, and the right lung was then lavaged three times by slowly instilling 0.5 ml of PBS (Ca$^{++}$ and Mg$^{++}$ free, 37 °C) and then gradually aspirating the lavaged fluid. The lower lobe of the left lung was excised for pulmonary water content evaluation. The upper lobe of the left lung was fixed in formalin for pathology examination and TUNEL assay. The remaining right lung lobes were individually frozen in liquid nitrogen for RNA extraction.

**Aerosol generation and exposure protocol**

ECIG aerosol was generated using pre-filled V4L CoolCart (3.5 Ohm, 18 mg/mL labeled nicotine concentration) cartomizer cartridges, connected to an automatically activated 4.2 V Vapor Titan Soft Touch battery. The cartridges and batteries were purchased from an internet vendor ([www.vapor4life.com](http://www.vapor4life.com)) and passed a quality control test before their use. To ensure a steady aerosol generation during the 3-hour exposure sessions, cartridges and batteries were replaced every 30 min. ECIG puff parameters were set at 4 s puff duration, 1.2 L/min flow rate, and 14 s inter-puff interval, as in Talih et al. [16].

HTP aerosols were generated utilizing the ‘I quit smoking system’ (IQOS). The tobacco sticks, holders and the batteries were purchased from the internet vendor ([www.IQOS.COM](http://www.IQOS.COM)). The holder was fully charged before its use and the tobacco sticks were replaced every 6 min. The puff duration was 2 sec and the time in-between the puffs was 58 sec (i.e. 1 puff for 2 seconds every 1 minute). The puff depth was 35 ml. CS was generated from 3R4F cigarettes (University of Kentucky, Lexington, KY) with 0.9 mg TPM, 9.4 mg tar, and 0.726 mg nicotine per cigarette. The machine was set at one puff every minute with a duration of two seconds per puff and a volume of 35 ml per puff as well. With the current setup, cotinine levels were sampled from different groups. CS animals displayed levels that ranged from (40 to 55 ng/ml) as compared to ECIG and HTP groups where levels were consistently > 100 ng/ml. Cotinine levels signified adequate exposure to HTP and ECIG when compared to CS. With the current utilized protocol, non-diabetic animals would be exposed to levels that will result in measurable lung injury (17). The differential effects on Diabetic mice can then be ascertained.

**Lung histology:**
The upper lobe of the right lung was fixed in 10% buffered formalin, embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E). The degree of lung injury was determined based on the following histological features: alveolar interstitial wall edema, congestion, degree of inflammatory cell infiltration, and intra-alveolar edema.

**Wet-to-dry lung weight**

The left lower lobe was weighed and then placed in a 95 °C oven to dry for two days. The dried tissue was weighed, and the wet-to-dry ratio (W/D) was then calculated.

**Albumin level**

The concentration of albumin in the BALF was determined by an immune-turbidimetric assay as described before (16). Agglutination, caused by antigen/antibody complexes, was measured turbidimetrically at the clinical chemistry laboratory of the American University of Beirut Medical Center using a Hitachi 912 Autoanalyser (Roche Diagnostics, Basel, Switzerland).

**Transcription expression profile of inflammatory mediators IL-1, IL-6, and TNF-α**

Quantitative Polymerase Chain Reaction (q-PCR) was utilized to assess inflammatory mediators’ transcriptional levels. RNA was extracted from the lung using the TRIzol method (Invitrogen, Carlsbad, CA, USA). Briefly, 1 ml of TRIzol reagent was used per 50–100 mg of a tissue sample, followed by chloroform extraction. RNA samples were precipitated and stored at -80 °C. RNA was quantified using a 260/280 nm absorbance ratio method. Total RNA (5 µg) was reverse-transcribed into first strand cDNA. Real time-PCR was performed using the iCycler (Bio-Rad Laboratories, Hercules, CA, USA) with SYBR Green. Specific primers (Tib-Molbiol, Berlin, Germany) were used to assess the expression of the inflammatory mediators in these tissues (*IL-1β*: Fw CACCTCTCAAGCAGAGCACAG, Rw GGGTCCATGGTGAAAGTCAAC; *IL-6*: Fw TCCTACCCCAACTTCCAATGCTC, Rw TTGGATGGTCTTGGTCCTTAGCC; *TNF-α*: Fw AATGGGCTCCCTCTCATCAGTTC, Rw TCTGCTTGGTGTCTTGCTACGAC). PCR products and their corresponding melting temperatures were analyzed using the iQ5 Optical System Software” (Bio-Rad Laboratories). Correction for loading was achieved by subtracting for local background and normalizing against the cDNA levels of the GAPDH housekeeping gene (*GAPDH*: Fw GTATTGGGCGCCTGGTCACC, Rw CGCTCCTGGAAAGATGGTGATGG).

**Assessment of Reactive Oxygen Species (ROS) production:**

Dihydroethidium (DHE) (Invitrogen, Molecular Probes, USA) (10 µmol/L dissolved in DMSO) was applied to lung sections and incubated in a light-protected humidified chamber at 37 °C for 15 min. Fluorescent images of ethidium-stained tissue were scanned for a signal with a scanning confocal microscope (LSM 710, Zeiss, Germany). Ethidium bromide was excited at 488 nm, and fluorescence was detected at 560 nm long-pass filter. Mean fluorescence intensity of the digitalized image was measured with Image
software [National Institutes of Health (NIH), Bethesda, MD] for quantification as previously described [16].

**Assessment of apoptosis – TUNEL assay**

The terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay was used to monitor the extent of DNA fragmentation. Fluorescein-conjugated dUTP incorporated in nucleotide polymers was detected and analyzed using fluorescence microscopy (Zeiss LSM 710, Germany). Positive and negative controls were used to verify the specificity of the TUNEL assay. TUNEL-positive nuclei were distinguished from the TUNEL-negative nuclei by counterstaining with Hoechst 33258.

**Results**

One animal in the Diab + CS expired on day six of CS exposure. All other animals in the different groups (Diab and Non-Diab) survived the experiment. CS animals displayed limited decrease in body weight that was statistically non-significant.

**Lung histology**

H&E staining of lung sections from Non-Diab + ECIG essentially displayed “normal” alveolar structure with isolated foci of infiltration of inflammatory cells (Figs. 1A and 1B). Diab + ECIG demonstrated worsening infiltration of inflammatory cells (macrophages and lymphocytes) around the bronchioles and into the lung parenchyma. Edematous and thickened alveolar walls were also noted (Fig. 1C and 1D).

Non-Diab + HTP lungs revealed patches of alveolar wall edema and capillary congestion (Figs. 1E and 1F). These findings were significantly worse in Diab + HTP when compared to Non-Diab + HTP. Non-Diab + CS and Diab + CS lungs demonstrated significant acute lung injury in both groups. Diab + CS lung injury was significantly worse when compared to Non-Diab + CS with worsening edematous and thickened alveolar walls, in addition to significant infiltration by inflammatory cells (Fig. 1).

**W/D Ratio and Albumin leak**

There was significant \( p < 0.001 \) increase in the W/D ratio, when compared to Control, for animals exposed to CS (Non-Diab and Diab). HTP and ECIG for both diabetic and Non-Diab animals demonstrated no any significant increase in W/D ratio when compared to Control. As for albumin leak into the BALF, no significant increase in albumin leak was noted in ECIG, but both HTP animals (Non-Diab and Diab) demonstrated significant \( p < 0.001 \) albumin leak into the BALF when compared to Control.

**Inflammatory Mediators**

**TNF-α**

Exposure to ECIG or HTP did not result in an increase in TNF-α in the Non-Diabetic group. On the other hand, Diab + ECIG and Diab + HTP demonstrated a significant increase in TNF-α expression when
compared to Non-Diab groups and Control (Fig. 2A). CS exposure resulted in a significant increase TNF-α in expression in Non-Diabetic and diabetic groups as well. The intensity of TNF-α expression was significantly higher in Diab group when compared to Non-Diab.

IL-1β:

Exposure to ECIG resulted in increased IL-1β expression in both Non-Diab and Diab groups when compared to Control. Exposure to HTP, however, resulted in increased IL-1β expression only in the diabetic group (Fig. 2B). Non-Diab + HTP IL-1β expression was similar to Control. CS exposure was associated with a surge IL-1β expression in both groups (Diab and non-Diab). The intensity of IL-1β expression of CS groups was significantly higher when compared to ECIG and HTP for Diab and Non-Diab groups respectively.

IL-6

The intensity of IL-6 expression was significantly increased in Diab + ECIG when compared to Non-Diab and Control (Fig. 2C). HTP exposure did not result in any significant increase in the IL-6 expression for Diabetic and Non-Diabetic groups. As described previously, CS exposure, IL-6 expression was significantly increased in both groups when compared to Control, and the expression of the Diab + CS was significantly greater than Non-Diab + CS.

Oxidative stress and apoptosis

HTP exposure did not result in any significant OS in Diab and Non-Diab animals. Diabetic mice exhibited a significant increase in ROS production in ECIG and CS groups when compared to Control and Non-Diabetic groups. CS-induced ROS were significantly higher in Diab + CS when compared to Non-Diab + CS. In the Non-Diab mice groups, OS was only observed in CS + Non-Diab when compared to Control (Fig. 3).

Similarly, a significant increase in the number of TUNEL positive, apoptotic nuclei, indicating cellular death, was detected in Diab + ECIG + and Diab + CS mice when compared to Control. The number of TUNEL-positive apoptotic nuclei was significantly higher with CS compared to ECIG exposure (Fig. 4). HTP exposure did not result in any significant increase in apoptosis in Diab + HTP nor Non-Diab + HTP.

Discussion

This study was designed to examine how diabetes mediates lung injury on exposure to ECIG, HTP, or CS aerosols. We found that when exposed to ECIG aerosols the lungs of diabetic mice demonstrated a significant increase in albumin leak, a surge in the expression of IL-1β, IL-6 and TNF-α and worsening OS and apoptosis. In addition, histopathological assessment of the lung tissue demonstrated worsening alveolar edema and infiltration by inflammatory cells. Non-Diabetic mice, exposed to ECIG aerosols, demonstrated lower severity of lung injury with ECIG exposure. IL-1β expression was the only tested inflammatory marker that was increased with ECIG exposure, but no significant surge was observed in IL-6, ROS production or apoptosis when compared to Control.
As for HTP exposure, there was no detectable increase in inflammation or lung injury in the Non-Diabetic group. Diab + HTP, however, was associated with a significant increase in TNF-α, IL-1β and when compared to Control. HTP exposure was, however, associated with significant albumin leak into the BALF. When HTP groups (Diab and not Diab) were compared to ECIG and CS groups, we concluded that HTP exposure was associated with the lowest injury to the lungs in this animal model. As for CS exposure, there was an increase in ROS, apoptosis and inflammatory mediators’ expression that was more pronounced in the diabetic group when compared to the Non-Diabetic group with similar CS exposure. The above findings suggest that diabetic mice are more vulnerable when exposed to external irritants such as those present in and ECIG, HTP or CS aerosol.

The association between comorbid health conditions and their augmentation of lung injury and inflammatory response secondary to illnesses and infections was reported in human and animal studies [18, 19]. Diabetes, in particular, is known to exacerbate systemic inflammation as evidenced by “priming the lung” with higher serum high mobility group box 1 (HMGB1), higher cytokine levels and enhanced lung injury in a systemic inflammation animal model [20, 21]. In addition, diabetes augments oxidant and pro-inflammatory cytokines expression in lung, liver, and heart in a septic animal model (22). The negative impact of diabetes on the lungs is observed in human epidemiological studies as higher fasting insulin and insulin resistance is associated with worsening pulmonary function testing [23, 24]. Other comorbid medical conditions have demonstrated an exacerbated response to CS with worsening lung injury as well. Crothers et al. [25], for example, examined the interplay of human immunodeficiency virus (HIV) as a comorbid medical condition with CS exposure and lung injury. The study observed worsening vulnerability of HIV-positive veterans to CS exposure by showing increased respiratory symptoms, COPD, and bacterial pneumonia which all resulted in their increased mortality and decreased quality of life [26].

**Conclusion**

This study highlights the importance of comorbid health conditions in amplifying inhalational lung injury in ECIG, HTP and combustible tobacco products consumers. While limited or no findings were noted in the Non-Diabetic mice exposed to HTP or ECIG for one week of exposure, significant lung injury was noted with ECIG exposure and to a lesser extent with HTP resulting in alveolar injury, increased OS and apoptosis and a significant surge in some of the inflammatory markers in diabetic mice. As more novel tobacco products are introduced into the global markets, it is critical to assess their harm and health effects not only on healthy subjects but also to extend the assessment to subjects with additional comorbid health conditions, such as diabetes.

**Abbreviations**

- CS
  - Cigarette smoke
- COPD
  - Chronic obstructive pulmonary disease
ECIG
Electronic cigarettes
HTTP
Heated tobacco products
ROS
Reactive Oxygen Species
OS
Oxidative stress
TUNEL
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling

Declarations

Acknowledgements

Not applicable

Author contribution

Ahmad Husari (AH) and Ghazi Zaatarí (GZ), and Alan Shihadeh (AS) designed and conceived the study. AH and Michella Abi Zeid Daou (MAD) supervised experiments and wrote the manuscript. Yasmine Hashem (YH), Hala Bitar (HB) and Alaa Kassir (AK) and Nareg Karaoghlanian performed and or contributed to the experiments, data acquisition and analysis. (AS) and Assaad A. Eid (AE) provided logistical and intellectual support. Marwan El Sabban and AS critically reviewed and corrected the manuscript. All authors approved submission.

Funding

This study was supported Medical Practice Plan at the American University of Beirut (AH). The National Institute on Drug Abuse of the National Institutes of Health (grant number P50DA036105) and the Center for Tobacco Products of the U.S. Food and Drug Administration (AS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the American University of Beirut, the National Institutes of Health, or the Food and Drug Administration.

Availability of data

The datas and material used in this the current study are available from the corresponding author on a reasonable request.

Ethics approval

All animal procedures were conducted according to the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use
Committee at the American University of Beirut

Competing Interests

The authors declare no competing financial and non-financial interests.

References

1. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1345–422. doi:10.1016/S0140-6736(17)32366-8.

2. Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389:1931–40. doi:10.1016/S0140-6736(17)31222-9.

3. Jha P, Chaloupka FJ, Moore J, Gajalakshmi V, Gupta PC, Peck R, Asma S, Zatonski W. Tobacco Addiction. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): World Bank; 2006. Chapter 46.

4. Grana R, Benowitz N, Glantz SA. Background Paper on ECIGarettes (Electronic Nicotine Delivery Systems). UCSF: Center for Tobacco Control Research and Education (2013). Retrieved from https://escholarship.org/uc/item/13p2b72n.

5. FDA. Summary of results: laboratory analysis of electronic cigarettes conducted by FDA. US Department of Health and Human Services website. http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm173146.htm. Accessed May 1, 2018.

6. Tierney PA, Karpinski CD, Brown JE, Luo W, Pankow JF. Flavor chemicals in electronic cigarette uids. Tob Control 2016: e10-5. doi:10.1136/tobaccocontrol-2014-052175.

7. 10.1111/add.13322
Farrimond H. ECIGarette regulation and policy: UK vapers’ perspectives. Addiction. 2016;111(6):1077–83. http://dx.doi.org/10.1111/add.13322 pmid: 26802864.

8. Annette R, Gabbi P, Shanta D, Rene A. Electronic nicotine delivery systems: adult use and awareness of the ‘ECIGarette’ in the USA. Tob Control. 2013;22:19–23.

9. Research and Market. Vapor Products Market (E-vapor and Heat-not-Burn Devices) - Global Outlook and Forecast 2018–2023. https://www.researchandmarkets.com/research/7chpjs/global_vapor?w=5.

10. Glantz SA. Heated tobacco products: the example of IQOS. Tob Control. 2018;27:s1–6.

11. Phillips B, Veljkovic E, Peck MJ, Buettner A, Elamin A, Guedj E, et al. A 7-month cigarette smoke inhalation study in C57BL/6 mice demonstrates reduced lung inflammation and emphysema following smoking cessation or aerosol exposure from a prototypic modified risk tobacco product. Food Chem Toxicol. 2015;80:328–45.
12. Szuszkiewicz-Garcia MM, Davidson JA. Cardiovascular disease in diabetes mellitus: risk factors and medical therapy. Endocrinol Metab Clin North Am. 2014;43:25–40. doi:10.1016/j.ecl.2013.09.001.

13. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Resp J. 2008;32:962e969. doi:10.1183/09031936.00012408.

14. Fagard RH. Smoking amplifies cardiovascular risk in patients with hypertension and diabetes. Diabetes Care. 2009;32:429-31. doi:10.2337/dc09-S354.

15. Husari A, Hashem Y, Zaatar G, El Sabban M. Pomegranate Juice Prevents the Formation of Lung Nodules Secondary to Chronic Cigarette Smoke Exposure in an Animal Model. Oxid Med Cell Longev. 2017;2017:6063201. doi:10.1155/2017/6063201.

16. Talih S, Balhas Z, Eissensseng T, Salman R, Karaoghlanian N, El-Hellani A, Baalbaki R, Saliba N, Shihadeh A. Effects of User Puff Topography, Device Voltage, and Liquid Nicotine Concentration on Electronic Cigarette Nicotine Yield: Measurements and Model Predictions. Nicotine Tob Res. 2015;17:150–7. doi:10.1093/ntr/ntu174.

17. Husari A, Shihadeh A, Talih S, Hashem Y, El Sabban M, Zaatar G. Acute Exposure to Electronic and Combustible Cigarette Aerosols: Effects in an Animal Model and in Human Alveolar Cells. Nicotine Tob Res. 2016;18:613–9. doi:10.1093/ntr/ntv169.

18. Pirola L, Ferraz JC. Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity. World J Biol Chem. 2017;8:120–8. doi:10.4331/wjbc.v8i2.120.

19. Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management. Semin Respir Crit Care Med. 2015;36:575–91. doi:10.1055/s-0035-1556063.

20. Boteanu RM, Uyy E, Suica VI, Antohe F. High-mobility group box 1 enhances the inflammatory process in diabetic lung. Arch Biochem Biophys. 2015;583:55–64. doi:10.1016/j.abb.2015.07.020.

21. Eid AA, Ford BM, Bhandary B, de Cassia Cavagliieri R, Block K, Barnes JL, Gorin Y, Choudhury GG, Abboud HE. Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury. Diabetes. 2013;62:2935–47. doi:10.2337/db12-1504.

22. Uyanik MH, Albayrak A, Odabasoglu F, Karakus E, Ozden K, Polat B, Yayla M, Karamese M, Albayrak A, Yazgi H. Effects of diabetes on cytokines and oxidative organ injury in a rat model of sepsis. Cell Mol Biol. 2012; 58 Suppl: OL1623-31. PubMed PMID: 22340705.

23. Sparrow D, Weiss ST. Baseline ventilatory function predicts the development of higher levels of fasting insulin and fasting insulin resistance index: The Normative Aging Study. Eur Respir J. 1998;12:641–5.

24. Van den Borst B, Gosker HR, Zeegers MP, Schols AM. Pulmonary function in diabetes: a meta-analysis. Chest. 2010;138:393–406. doi:10.1378/chest.09-2622.

25. Crothers K, Tephany A, Griffith MPH, et al. The Impact of Cigarette Smoking on Mortality, Quality of Life, and Comorbid Illness among HIV-Positive Veterans. J Gen Intern Med. 2005;20:1142–5.
Figure 1

Histology of lungs of Non-Diabetic vs Diabetic after seven days of ECIG, HTP and CS exposure. Non-Diabetic lungs + ECIG showing limited lung injury with thin interstitial alveolar wall and fine capillary vessels (Figure 1A; magnification x 20). Rare inflammatory cells in the wall and intra-alveolar spaces are noted (Figure 1B; magnification x 40). Sections from Diabetic + ECIG lungs demonstrate limited areas of thickening of the interstitial wall, capillary congestion and limited areas of inflammation (Figure 1C; magnification x 20). Arrows point to a significant presence of inflammatory cells (Figure 1D; magnification x 40). Non-Diabetic lungs + HTP showing patches of alveolar wall edema and capillary
congestion (Figure 1E; magnification x 20). Those findings were significantly worse in Diabetic lungs exposed to HTP (Figure 1F; magnification x 20). Arrows point to presence of inflammatory cells (Figure 1H; magnification x 40). Non-diabetic lungs showing significant lung injury with thick interstitial alveolar walls and capillary congestion (Figure 1J; magnification X20). Inflammatory cells in the wall and intra-alveolar spaces are noted (Figure 1K; magnification x40). Sections from Diabetic lungs demonstrate worsening lung injury when compared to non-diabetic animals with destruction of the alveolar architecture and edematous distension of the alveolar sacs (Figure 1L; magnification x 20). Worsening recruitment of inflammatory cells is now observed as well (Figure 1M; magnification x 40).
Figure 2

Transcriptional expression of IL-1β (C), IL-6 (D) and TNF-α (F) of Control, ECIG and CS for Diabetic and Non-Diabetic mice. Expression of inflammatory mediators was assessed by real-time PCR. Error bars represent SE. Asterisks indicate statistically significant associations (P < 0.05).
**Figure 3**

ROS detection in lung tissues. Five μm thickness slides of lung sections for Control, ECIG and CS from Non-Diabetic and diabetic mice were incubated with Dihydroethidium (DHE), and fluorescent images of ethidium-stained tissue were analyzed. ROS levels were significantly higher in ECIG and CS and exposed diabetic mice when compared to ECIG and CS Non-Diabetic mice exposure respectively.
Cell death assessment. Terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling (TUNEL) and Hoechst staining of lung sections for Control, ECIG and CS from diabetic and Non-Diabetic mice. Significant increase in apoptotic activity was noted in ECIG and CS and exposed diabetic mice when compared to ECIG and CS Non-Diabetic mice respectively.